葛兰素史克新可来在中国获批用于治疗成人慢性阻塞性肺疾病

Core Viewpoint - GlaxoSmithKline China announced that the National Medical Products Administration (NMPA) has approved Nucala (mepolizumab injection) for maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) characterized by eosinophilic inflammation that is not adequately controlled [1] Group 1 - The approval of Nucala is specifically for adult patients with COPD who have elevated eosinophils [1] - This treatment aims to address the unmet medical needs in the COPD patient population [1] - Nucala is expected to enhance the management of COPD in China, providing a new therapeutic option [1]